{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T19:30:29Z","timestamp":1695324629870},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,11,24]],"date-time":"2016-11-24T00:00:00Z","timestamp":1479945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,11,24]],"date-time":"2016-11-24T00:00:00Z","timestamp":1479945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A majority of adults without HIV infection and with a low risk of HIV-exposure have plasma IgG antibodies that enhance the rate and magnitude of HIV-induced interferon alpha (IFN-\u03b1) production. Fc-dependent IgG-HIV complexes induce IFN-\u03b1 rapidly and in high titers in response to HIV concentrations that are too low to otherwise stimulate an effective IFN-\u03b1 response. IFN-\u03b1 promoting antibody (IPA) counters HIV-specific inhibition of IFN-\u03b1 production, and compensates for the inherent delay in IFN-\u03b1 production common to HIV infection and other viruses. Naturally occurring IPA has the potential to initiate a potent IFN-\u03b1 response early in the course of HIV mucosal invasion in time to terminate infection prior to the creation of a pool of persistently infected cells. The current study adds IPA as a mediator of an Fc-dependent antiviral state capable of preventing HIV infection.<\/jats:p>","DOI":"10.1038\/srep37493","type":"journal-article","created":{"date-parts":[[2016,11,24]],"date-time":"2016-11-24T10:05:38Z","timestamp":1479981938000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Naturally Occurring Fc-Dependent Antibody From HIV-Seronegative Individuals Promotes HIV-Induced IFN-\u03b1 Production"],"prefix":"10.1038","volume":"6","author":[{"given":"Thomas","family":"Lum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon A.","family":"Green","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,24]]},"reference":[{"key":"BFsrep37493_CR1","unstructured":"Centers for Disease Control and Prevention. HIV Transmission Risk, http:\/\/www.cdc.gov\/hiv\/policies\/law\/risk.html (2014)."},{"key":"BFsrep37493_CR2","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/COH.0b013e3283495996","volume":"6","author":"P Borrow","year":"2011","unstructured":"Borrow, P. Innate immunity in acute HIV-1 infection. Current opinion in HIV and AIDS 6, 353\u2013363, doi: 10.1097\/COH.0b013e3283495996 (2011).","journal-title":"Current opinion in HIV and AIDS"},{"key":"BFsrep37493_CR3","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1093\/infdis\/jir747","volume":"205","author":"JP Hughes","year":"2012","unstructured":"Hughes, J. P. et al. Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. The Journal of infectious diseases 205, 358\u2013365, doi: 10.1093\/infdis\/jir747 (2012).","journal-title":"The Journal of infectious diseases"},{"key":"BFsrep37493_CR4","doi-asserted-by":"publisher","first-page":"e1002686","DOI":"10.1371\/journal.ppat.1002686","volume":"8","author":"NF Parrish","year":"2012","unstructured":"Parrish, N. F. et al. Transmitted\/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin alpha4beta7. PLoS pathogens 8, e1002686, doi: 10.1371\/journal.ppat.1002686 (2012).","journal-title":"PLoS pathogens"},{"key":"BFsrep37493_CR5","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/1742-4690-10-146","volume":"10","author":"AE Fenton-May","year":"2013","unstructured":"Fenton-May, A. E. et al. Relative resistance of HIV-1 founder viruses to control by interferon-alpha. Retrovirology 10, 146, doi: 10.1186\/1742-4690-10-146 (2013).","journal-title":"Retrovirology"},{"key":"BFsrep37493_CR6","doi-asserted-by":"publisher","first-page":"7552","DOI":"10.1073\/pnas.0802203105","volume":"105","author":"BF Keele","year":"2008","unstructured":"Keele, B. F. et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America 105, 7552\u20137557, doi: 10.1073\/pnas.0802203105 (2008).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"BFsrep37493_CR7","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1006\/viro.1993.1126","volume":"193","author":"Y Shirazi","year":"1993","unstructured":"Shirazi, Y. & Pitha, P. M. Interferon alpha-mediated inhibition of human immunodeficiency virus type 1 provirus synthesis in T-cells. Virology 193, 303\u2013312, doi: 10.1006\/viro.1993.1126 (1993).","journal-title":"Virology"},{"key":"BFsrep37493_CR8","doi-asserted-by":"publisher","first-page":"10527","DOI":"10.1128\/JVI.01235-09","volume":"83","author":"D Vendrame","year":"2009","unstructured":"Vendrame, D., Sourisseau, M., Perrin, V., Schwartz, O. & Mammano, F. Partial inhibition of human immunodeficiency virus replication by type I interferons: impact of cell-to-cell viral transfer. Journal of virology 83, 10527\u201310537, doi: 10.1128\/JVI.01235-09 (2009).","journal-title":"Journal of virology"},{"key":"BFsrep37493_CR9","first-page":"43","volume":"16","author":"A Sivro","year":"2014","unstructured":"Sivro, A., Su, R. C., Plummer, F. A. & Ball, T. B. Interferon responses in HIV infection: from protection to disease. AIDS reviews 16, 43\u201351 (2014).","journal-title":"AIDS reviews"},{"key":"BFsrep37493_CR10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1001\/archinte.1970.00310070086008","volume":"126","author":"S Baron","year":"1970","unstructured":"Baron, S. The biological significance of the interferon system. Archives of internal medicine 126, 84\u201393 (1970).","journal-title":"Archives of internal medicine"},{"key":"BFsrep37493_CR11","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1001\/jama.1991.03470100067035","volume":"266","author":"S Baron","year":"1991","unstructured":"Baron, S. et al. The interferons. Mechanisms of action and clinical applications. Jama 266, 1375\u20131383 (1991).","journal-title":"Jama"},{"key":"BFsrep37493_CR12","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1126\/science.1125676","volume":"312","author":"A Garcia-Sastre","year":"2006","unstructured":"Garcia-Sastre, A. & Biron, C. A. Type 1 interferons and the virus-host relationship: a lesson in detente. Science 312, 879\u2013882, doi: 10.1126\/science.1125676 (2006).","journal-title":"Science"},{"key":"BFsrep37493_CR13","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S0300-9084(99)80028-5","volume":"80","author":"F Dianzani","year":"1998","unstructured":"Dianzani, F. et al. Effects of IFN alpha on late stages of HIV-1 replication cycle. Biochimie 80, 745\u2013754 (1998).","journal-title":"Biochimie"},{"key":"BFsrep37493_CR14","doi-asserted-by":"publisher","first-page":"e37052","DOI":"10.1371\/journal.pone.0037052","volume":"7","author":"CC Lo","year":"2012","unstructured":"Lo, C. C. et al. HIV delays IFN-alpha production from human plasmacytoid dendritic cells and is associated with SYK phosphorylation. PloS one 7, e37052, doi: 10.1371\/journal.pone.0037052 (2012).","journal-title":"PloS one"},{"key":"BFsrep37493_CR15","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1073\/pnas.0611353104","volume":"104","author":"E Martinelli","year":"2007","unstructured":"Martinelli, E. et al. HIV-1 gp120 inhibits TLR9-mediated activation and IFN-{alpha} secretion in plasmacytoid dendritic cells. Proceedings of the National Academy of Sciences of the United States of America 104, 3396\u20133401, doi: 10.1073\/pnas.0611353104 (2007).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"BFsrep37493_CR16","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.virol.2015.03.015","volume":"482","author":"P Mlcochova","year":"2015","unstructured":"Mlcochova, P. et al. Immune evasion activities of accessory proteins Vpu, Nef and Vif are conserved in acute and chronic HIV-1 infection. Virology 482, 72\u201378, doi: 10.1016\/j.virol.2015.03.015 (2015).","journal-title":"Virology"},{"key":"BFsrep37493_CR17","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1089\/10799900260475722","volume":"22","author":"JA Green","year":"2002","unstructured":"Green, J. A. et al. Immune-specific immunoglobulin G-mediated enhancement of human immunodeficiency virus-induced IFN-alpha production. Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research 22, 1201\u20131208, doi: 10.1089\/10799900260475722 (2002).","journal-title":"Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research"},{"key":"BFsrep37493_CR18","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1006\/viro.2000.0627","volume":"278","author":"P Palmer","year":"2000","unstructured":"Palmer, P., Charley, B., Rombaut, B., Daeron, M. & Lebon, P. Antibody-dependent induction of type I interferons by poliovirus in human mononuclear blood cells requires the type II fcgamma receptor (CD32). Virology 278, 86\u201394, doi: 10.1006\/viro.2000.0627 (2000).","journal-title":"Virology"},{"key":"BFsrep37493_CR19","doi-asserted-by":"publisher","first-page":"13882","DOI":"10.1128\/JVI.79.22.13882-13891.2005","volume":"79","author":"W Chehadeh","year":"2005","unstructured":"Chehadeh, W. et al. Viral protein VP4 is a target of human antibodies enhancing coxsackievirus B4- and B3-induced synthesis of alpha interferon. Journal of virology 79, 13882\u201313891, doi: 10.1128\/JVI.79.22.13882-13891.2005 (2005).","journal-title":"Journal of virology"},{"key":"BFsrep37493_CR20","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1002\/eji.200635866","volume":"36","author":"L Guzylack-Piriou","year":"2006","unstructured":"Guzylack-Piriou, L., Bergamin, F., Gerber, M., McCullough, K. C. & Summerfield, A. Plasmacytoid dendritic cell activation by foot-and-mouth disease virus requires immune complexes. European journal of immunology 36, 1674\u20131683, doi: 10.1002\/eji.200635866 (2006).","journal-title":"European journal of immunology"},{"key":"BFsrep37493_CR21","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.1128\/JVI.02495-10","volume":"85","author":"E Reid","year":"2011","unstructured":"Reid, E. et al. Bovine plasmacytoid dendritic cells are the major source of type I interferon in response to foot-and-mouth disease virus in vitro and in vivo. Journal of virology 85, 4297\u20134308, doi: 10.1128\/JVI.02495-10 (2011).","journal-title":"Journal of virology"},{"key":"BFsrep37493_CR22","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1002\/eji.200525998","volume":"35","author":"C Balmelli","year":"2005","unstructured":"Balmelli, C. et al. Fc gamma RII-dependent sensitisation of natural interferon-producing cells for viral infection and interferon-alpha responses. European journal of immunology 35, 2406\u20132415, doi: 10.1002\/eji.200525998 (2005).","journal-title":"European journal of immunology"},{"key":"BFsrep37493_CR23","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1086\/323801","volume":"184","author":"D Hober","year":"2001","unstructured":"Hober, D., Chehadeh, W., Bouzidi, A. & Wattre, P. Antibody-dependent enhancement of coxsackievirus B4 infectivity of human peripheral blood mononuclear cells results in increased interferon-alpha synthesis. The Journal of infectious diseases 184, 1098\u20131108, doi: 10.1086\/323801 (2001).","journal-title":"The Journal of infectious diseases"},{"key":"BFsrep37493_CR24","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1002\/jmv.21232","volume":"80","author":"DS Green","year":"2008","unstructured":"Green, D. S., Lum, T., Mullins, B. T. & Green, J. A. Antibody-mediated enhancement of the rate, magnitude, and responsiveness of vesicular stomatitis virus induced alpha interferon production. Journal of medical virology 80, 1675\u20131683, doi: 10.1002\/jmv.21232 (2008).","journal-title":"Journal of medical virology"},{"key":"BFsrep37493_CR25","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1128\/AAC.01246-09","volume":"54","author":"JA Martinson","year":"2010","unstructured":"Martinson, J. A. et al. Chloroquine modulates HIV-1-induced plasmacytoid dendritic cell alpha interferon: implication for T-cell activation. Antimicrobial agents and chemotherapy 54, 871\u2013881, doi: 10.1128\/AAC.01246-09 (2010).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"BFsrep37493_CR26","first-page":"55","volume":"24","author":"BE van den Borne","year":"1997","unstructured":"van den Borne, B. E., Dijkmans, B. A., de Rooij, H. H., le Cessie, S. & Verweij, C. L. Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. The Journal of rheumatology 24, 55\u201360 (1997).","journal-title":"The Journal of rheumatology"},{"key":"BFsrep37493_CR27","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1128\/iai.20.1.55-57.1978","volume":"20","author":"F Dianzani","year":"1978","unstructured":"Dianzani, F., Gullino, P. & Baron, S. Rapid activation of the interferon system in vivo. Infection and immunity 20, 55\u201357 (1978).","journal-title":"Infection and immunity"},{"key":"BFsrep37493_CR28","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1128\/JVI.07114-11","volume":"86","author":"K Machmach","year":"2012","unstructured":"Machmach, K. et al. Plasmacytoid dendritic cells reduce HIV production in elite controllers. Journal of virology 86, 4245\u20134252, doi: 10.1128\/JVI.07114-11 (2012).","journal-title":"Journal of virology"},{"key":"BFsrep37493_CR29","doi-asserted-by":"publisher","first-page":"2772","DOI":"10.4049\/jimmunol.1003208","volume":"186","author":"S Terawaki","year":"2011","unstructured":"Terawaki, S. et al. IFN-alpha directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. Journal of immunology 186, 2772\u20132779, doi: 10.4049\/jimmunol.1003208 (2011).","journal-title":"Journal of immunology"},{"key":"BFsrep37493_CR30","doi-asserted-by":"publisher","first-page":"17453","DOI":"10.1073\/pnas.0707244104","volume":"104","author":"AW Hardy","year":"2007","unstructured":"Hardy, A. W., Graham, D. R., Shearer, G. M. & Herbeuval, J. P. HIV turns plasmacytoid dendritic cells (pDC) into TRAIL-expressing killer pDC and down-regulates HIV coreceptors by Toll-like receptor 7-induced IFN-alpha. Proceedings of the National Academy of Sciences of the United States of America 104, 17453\u201317458, doi: 10.1073\/pnas.0707244104 (2007).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"BFsrep37493_CR31","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/nature13554","volume":"511","author":"NG Sandler","year":"2014","unstructured":"Sandler, N. G. et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature 511, 601\u2013605, doi: 10.1038\/nature13554 (2014).","journal-title":"Nature"},{"key":"BFsrep37493_CR32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11904-014-0244-6","volume":"12","author":"SE Bosinger","year":"2015","unstructured":"Bosinger, S. E. & Utay, N. S. Type I interferon: understanding its role in HIV pathogenesis and therapy. Current HIV\/AIDS reports 12, 41\u201353, doi: 10.1007\/s11904-014-0244-6 (2015).","journal-title":"Current HIV\/AIDS reports"},{"key":"BFsrep37493_CR33","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/infdis\/jis663","volume":"207","author":"L Azzoni","year":"2013","unstructured":"Azzoni, L. et al. Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. The Journal of infectious diseases 207, 213\u2013222, doi: 10.1093\/infdis\/jis663 (2013).","journal-title":"The Journal of infectious diseases"},{"key":"BFsrep37493_CR34","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1093\/infdis\/jis667","volume":"207","author":"LA McNamara","year":"2013","unstructured":"McNamara, L. A. & Collins, K. L. Interferon alfa therapy: toward an improved treatment for HIV infection. The Journal of infectious diseases 207, 201\u2013203, doi: 10.1093\/infdis\/jis667 (2013).","journal-title":"The Journal of infectious diseases"},{"key":"BFsrep37493_CR35","doi-asserted-by":"publisher","first-page":"12676","DOI":"10.1128\/JVI.01893-12","volume":"86","author":"DN Sather","year":"2012","unstructured":"Sather, D. N. et al. Broadly neutralizing antibodies developed by an HIV-positive elite neutralizer exact a replication fitness cost on the contemporaneous virus. Journal of virology 86, 12676\u201312685, doi: 10.1128\/JVI.01893-12 (2012).","journal-title":"Journal of virology"},{"key":"BFsrep37493_CR36","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/nature07930","volume":"458","author":"JF Scheid","year":"2009","unstructured":"Scheid, J. F. et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458, 636\u2013640, doi: 10.1038\/nature07930 (2009).","journal-title":"Nature"},{"key":"BFsrep37493_CR37","doi-asserted-by":"publisher","first-page":"4688","DOI":"10.1128\/JVI.07163-11","volume":"86","author":"M Bonsignori","year":"2012","unstructured":"Bonsignori, M. et al. Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. Journal of virology 86, 4688\u20134692, doi: 10.1128\/JVI.07163-11 (2012).","journal-title":"Journal of virology"},{"key":"BFsrep37493_CR38","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/imr.12075","volume":"254","author":"JR Mascola","year":"2013","unstructured":"Mascola, J. R. & Haynes, B. F. HIV-1 neutralizing antibodies: understanding nature\u2019s pathways. Immunological reviews 254, 225\u2013244, doi: 10.1111\/imr.12075 (2013).","journal-title":"Immunological reviews"},{"key":"BFsrep37493_CR39","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature06106","volume":"449","author":"AJ Hessell","year":"2007","unstructured":"Hessell, A. J. et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449, 101\u2013104, doi: 10.1038\/nature06106 (2007).","journal-title":"Nature"},{"key":"BFsrep37493_CR40","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/j.cell.2015.06.003","volume":"161","author":"P Dosenovic","year":"2015","unstructured":"Dosenovic, P. et al. Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice. Cell 161, 1505\u20131515, doi: 10.1016\/j.cell.2015.06.003 (2015).","journal-title":"Cell"},{"key":"BFsrep37493_CR41","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/nature11604","volume":"492","author":"F Klein","year":"2012","unstructured":"Klein, F. et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492, 118\u2013122, doi: 10.1038\/nature11604 (2012).","journal-title":"Nature"},{"key":"BFsrep37493_CR42","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1128\/JVI.01272-09","volume":"84","author":"AJ Hessell","year":"2010","unstructured":"Hessell, A. J. et al. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. Journal of virology 84, 1302\u20131313, doi: 10.1128\/JVI.01272-09 (2010).","journal-title":"Journal of virology"},{"key":"BFsrep37493_CR43","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/nature17677","volume":"533","author":"R Gautam","year":"2016","unstructured":"Gautam, R. et al. A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature 533, 105\u2013109, doi: 10.1038\/nature17677 (2016).","journal-title":"Nature"},{"key":"BFsrep37493_CR44","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.cell.2014.08.023","volume":"158","author":"S Bournazos","year":"2014","unstructured":"Bournazos, S. et al. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 158, 1243\u20131253, doi: 10.1016\/j.cell.2014.08.023 (2014).","journal-title":"Cell"},{"key":"BFsrep37493_CR45","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/mi.2013.23","volume":"7","author":"C Moog","year":"2014","unstructured":"Moog, C. et al. Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques. Mucosal immunology 7, 46\u201356, doi: 10.1038\/mi.2013.23 (2014).","journal-title":"Mucosal immunology"},{"key":"BFsrep37493_CR46","doi-asserted-by":"publisher","first-page":"8672","DOI":"10.1128\/JVI.00287-12","volume":"86","author":"A Smalls-Mantey","year":"2012","unstructured":"Smalls-Mantey, A. et al. Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding. Journal of virology 86, 8672\u20138680, doi: 10.1128\/JVI.00287-12 (2012).","journal-title":"Journal of virology"},{"key":"BFsrep37493_CR47","doi-asserted-by":"publisher","first-page":"4466","DOI":"10.1182\/blood-2005-08-3490","volume":"107","author":"V Holl","year":"2006","unstructured":"Holl, V. et al. Efficient inhibition of HIV-1 replication in human immature monocyte-derived dendritic cells by purified anti-HIV-1 IgG without induction of maturation. Blood 107, 4466\u20134474, doi: 10.1182\/blood-2005-08-3490 (2006).","journal-title":"Blood"},{"key":"BFsrep37493_CR48","doi-asserted-by":"publisher","first-page":"6177","DOI":"10.1128\/JVI.02625-05","volume":"80","author":"V Holl","year":"2006","unstructured":"Holl, V. et al. Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. Journal of virology 80, 6177\u20136181, doi: 10.1128\/JVI.02625-05 (2006).","journal-title":"Journal of virology"},{"key":"BFsrep37493_CR49","doi-asserted-by":"publisher","first-page":"6953","DOI":"10.1128\/JVI.75.15.6953-6961.2001","volume":"75","author":"DN Forthal","year":"2001","unstructured":"Forthal, D. N., Landucci, G. & Daar, E. S. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. Journal of virology 75, 6953\u20136961, doi: 10.1128\/JVI.75.15.6953-6961.2001 (2001).","journal-title":"Journal of virology"},{"key":"BFsrep37493_CR50","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nature13612","volume":"514","author":"SY Ko","year":"2014","unstructured":"Ko, S. Y. et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 514, 642\u2013645, doi: 10.1038\/nature13612 (2014).","journal-title":"Nature"},{"key":"BFsrep37493_CR51","doi-asserted-by":"publisher","first-page":"10844","DOI":"10.1038\/ncomms10844","volume":"7","author":"T Bruel","year":"2016","unstructured":"Bruel, T. et al. Elimination of HIV-1-infected cells by broadly neutralizing antibodies. Nature communications 7, 10844, doi: 10.1038\/ncomms10844 (2016).","journal-title":"Nature communications"},{"key":"BFsrep37493_CR52","doi-asserted-by":"publisher","first-page":"e1005042","DOI":"10.1371\/journal.ppat.1005042","volume":"11","author":"S Santra","year":"2015","unstructured":"Santra, S. et al. Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. PLoS pathogens 11, e1005042, doi: 10.1371\/journal.ppat.1005042 (2015).","journal-title":"PLoS pathogens"},{"key":"BFsrep37493_CR53","doi-asserted-by":"publisher","first-page":"e1005154","DOI":"10.1371\/journal.ppat.1005154","volume":"11","author":"MJ Deymier","year":"2015","unstructured":"Deymier, M. J. et al. Heterosexual Transmission of Subtype C HIV-1 Selects Consensus-Like Variants without Increased Replicative Capacity or Interferon-alpha Resistance. PLoS pathogens 11, e1005154, doi: 10.1371\/journal.ppat.1005154 (2015).","journal-title":"PLoS pathogens"},{"key":"BFsrep37493_CR54","doi-asserted-by":"publisher","first-page":"12776","DOI":"10.1128\/JVI.00901-13","volume":"87","author":"SB Serre","year":"2013","unstructured":"Serre, S. B., Krarup, H. B., Bukh, J. & Gottwein, J. M. Identification of alpha interferon-induced envelope mutations of hepatitis C virus in vitro associated with increased viral fitness and interferon resistance. Journal of virology 87, 12776\u201312793, doi: 10.1128\/JVI.00901-13 (2013).","journal-title":"Journal of virology"},{"key":"BFsrep37493_CR55","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1084\/jem.20110363","volume":"208","author":"HX Liao","year":"2011","unstructured":"Liao, H. X. et al. Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. The Journal of experimental medicine 208, 2237\u20132249, doi: 10.1084\/jem.20110363 (2011).","journal-title":"The Journal of experimental medicine"},{"key":"BFsrep37493_CR56","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1084\/jem.20130555","volume":"211","author":"SL Campion","year":"2014","unstructured":"Campion, S. L. et al. Proteome-wide analysis of HIV-specific naive and memory CD4(+) T cells in unexposed blood donors. The Journal of experimental medicine 211, 1273\u20131280, doi: 10.1084\/jem.20130555 (2014).","journal-title":"The Journal of experimental medicine"},{"key":"BFsrep37493_CR57","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.immuni.2012.10.021","volume":"38","author":"LF Su","year":"2013","unstructured":"Su, L. F., Kidd, B. A., Han, A., Kotzin, J. J. & Davis, M. M. Virus-specific CD4(+) memory-phenotype T cells are abundant in unexposed adults. Immunity 38, 373\u2013383, doi: 10.1016\/j.immuni.2012.10.021 (2013).","journal-title":"Immunity"},{"key":"BFsrep37493_CR58","doi-asserted-by":"publisher","first-page":"6626","DOI":"10.1073\/pnas.1304288110","volume":"110","author":"NF Parrish","year":"2013","unstructured":"Parrish, N. F. et al. Phenotypic properties of transmitted founder HIV-1. Proceedings of the National Academy of Sciences of the United States of America 110, 6626\u20136633, doi: 10.1073\/pnas.1304288110 (2013).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"BFsrep37493_CR59","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.chom.2014.07.003","volume":"16","author":"AM Trama","year":"2014","unstructured":"Trama, A. M. et al. HIV-1 envelope gp41 antibodies can originate from terminal ileum B cells that share cross-reactivity with commensal bacteria. Cell host & microbe 16, 215\u2013226, doi: 10.1016\/j.chom.2014.07.003 (2014).","journal-title":"Cell host & microbe"},{"key":"BFsrep37493_CR60","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2217\/fnl.14.62","volume":"10","author":"X Xu","year":"2015","unstructured":"Xu, X. et al. Human-derived natural antibodies: biomarkers and potential therapeutics. Future neurology 10, 25\u201339, doi: 10.2217\/fnl.14.62 (2015).","journal-title":"Future neurology"},{"key":"BFsrep37493_CR61","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.2174\/1871520615666150716104935","volume":"15","author":"A Jarossay","year":"2015","unstructured":"Jarossay, A., Hadzhieva, M., Kaveri, S. V., Lacroix-Desmazes, S. & Dimitrov, J. D. Natural and Induced Antibody Polyreactivity. Anti-cancer agents in medicinal chemistry 15, 1230\u20131241 (2015).","journal-title":"Anti-cancer agents in medicinal chemistry"},{"key":"BFsrep37493_CR62","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/0952-7915(95)80053-0","volume":"7","author":"A Coutinho","year":"1995","unstructured":"Coutinho, A., Kazatchkine, M. D. & Avrameas, S. Natural autoantibodies. Current opinion in immunology 7, 812\u2013818 (1995).","journal-title":"Current opinion in immunology"},{"key":"BFsrep37493_CR63","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.chom.2016.02.002","volume":"19","author":"BF Haynes","year":"2016","unstructured":"Haynes, B. F. et al. HIV-Host Interactions: Implications for Vaccine Design. Cell host & microbe 19, 292\u2013303, doi: 10.1016\/j.chom.2016.02.002 (2016).","journal-title":"Cell host & microbe"},{"key":"BFsrep37493_CR64","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.4049\/jimmunol.127.3.1192","volume":"127","author":"JA Green","year":"1981","unstructured":"Green, J. A., Yeh, T. J. & Overall, J. C. Jr. Sequential production of IFN-alpha and immune-specific IFN-gamma by human mononuclear leukocytes exposed to herpes simplex virus. Journal of immunology 127, 1192\u20131196 (1981).","journal-title":"Journal of immunology"},{"key":"BFsrep37493_CR65","doi-asserted-by":"publisher","first-page":"7678","DOI":"10.1073\/pnas.89.16.7678","volume":"89","author":"H Chen","year":"1992","unstructured":"Chen, H., Boyle, T. J., Malim, M. H., Cullen, B. R. & Lyerly, H. K. Derivation of a biologically contained replication system for human immunodeficiency virus type 1. Proceedings of the National Academy of Sciences of the United States of America 89, 7678\u20137682 (1992).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"BFsrep37493_CR66","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1128\/jcm.16.2.413-415.1982","volume":"16","author":"TJ Yeh","year":"1982","unstructured":"Yeh, T. J., McBride, P. T., Overall, J. C. Jr. & Green, J. A. Automated, quantitative cytopathic effect reduction assay for interferon. Journal of clinical microbiology 16, 413\u2013415 (1982).","journal-title":"Journal of clinical microbiology"},{"key":"BFsrep37493_CR67","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1177\/0091270004267808","volume":"44","author":"MA Kamal","year":"2004","unstructured":"Kamal, M. A. & Jusko, W. J. Interactions of prednisolone and other immunosuppressants used in dual treatment of systemic lupus erythematosus in lymphocyte proliferation assays. Journal of clinical pharmacology 44, 1034\u20131045, doi: 10.1177\/0091270004267808 (2004).","journal-title":"Journal of clinical pharmacology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep37493.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep37493","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep37493.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T02:30:42Z","timestamp":1672885842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep37493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,24]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,23]]}},"alternative-id":["BFsrep37493"],"URL":"https:\/\/doi.org\/10.1038\/srep37493","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,24]]},"assertion":[{"value":"25 April 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37493"}}